Clinical trial

A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC

NCT04959981

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention ERAS-007 Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention ERAS-601 Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Osimertinib Normalized identity: osimertinibView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Sotorasib Normalized identity: sotorasibView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2021-09-02

PhasePHASE1

Conditions

Advanced Non-squamous Non-small-cell Lung Cancerunresolved

Interventions

ERAS-007DRUG

ERAS-601DRUG

OsimertinibDRUG · verified · RxNorm: osimertinib

SotorasibDRUG · verified · RxNorm: sotorasib

Sponsors & collaborators

Erasca, Inc.lead sponsor

Mapped research locations

BostonMassachusetts, United States2 New YorkNew York, United States1 NashvilleTennessee, United States1 AuroraColorado, United States1 DetroitMichigan, United States1 OrangeCalifornia, United States1 FairfaxVirginia, United States1 DuarteCalifornia, United States1 Santa MonicaCalifornia, United States1 HackensackNew Jersey, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04959981 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.